Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 9:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 114 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Topical Vehicle Gel Clear all
Terminated Phase 2 Interventional Results available

A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC

NCT04155190
View directory record Official record
Conditions
Recurrent Basal Cell Carcinoma
Interventions
Patidegib Topical Gel, 2%, Patidegib Topical Gel, Vehicle
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
14
States / cities
Apple Valley, California • Colton, California • Fremont, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 6, 2026, 9:15 PM EDT
Not listed Phase 2Phase 3 Interventional

Safety and Efficacy of Pro-ocular™ 1% in Daily Scleral Lens Wearing Patients With Ocular Graft-versus-Host Disease

NCT04769648
View directory record Official record
Conditions
Ocular Graft-versus-host Disease
Interventions
Pro-ocular™ Topical Gel 1%, Placebo
Drug
Lead sponsor
Glia, LLC
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Sep 6, 2026, 9:15 PM EDT
Completed Phase 1 Interventional

Safety and Efficacy of Topical TolaSure Targeting Aggregated Mutant Keratin in Severe Epidermolysis Bullosa Simplex

NCT05062070
View directory record Official record
Conditions
Epidermolysis Bullosa Simplex
Interventions
TolaSure Topical Gel, Vehicle Topical Gel
Drug
Lead sponsor
BioMendics, LLC
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2023 · Synced Sep 6, 2026, 9:15 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy of Topical TolaSure on Acute Induced Wounds in Healthy Participants

NCT04088357
View directory record Official record
Conditions
Wound Healing
Interventions
TolaSure Topical Gel, Topical Vehicle Gel
Drug
Lead sponsor
BioMendics, LLC
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Miami, Florida • College Station, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Sep 6, 2026, 9:15 PM EDT
Completed Phase 3 Interventional

A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea

NCT02393937
View directory record Official record
Conditions
Papulopustular Rosacea, Erythematotelangiectatic Rosacea
Interventions
Reference: Metronidazole Gel 1%, Test: Metronidazole Gel 1%, Placebo Gel
Drug
Lead sponsor
bioRASI, LLC
Industry
Eligibility
18 Years and older
Enrollment
963 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
27
States / cities
Los Angeles, California • San Diego, California • Boca Raton, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Sep 6, 2026, 9:15 PM EDT
Not listed Phase 2 Interventional

Topical Minocycline Gel for Inflammatory Lesions of Papulopustular Rosacea

NCT03667222
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
minocycline topical gel, topical gel vehicle
Drug
Lead sponsor
BioPharmX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
12
States / cities
Anaheim Hills, California • Miami, Florida • Miramar, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Sep 6, 2026, 9:15 PM EDT
Completed Phase 3 Interventional

Trial of Dapsone 5.0% Gel in the Treatment of Acne Vulgaris

NCT02865005
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Dapsone 5.0% Gel (SEEGPharm), Placebo, Dapsone 5.0% Gel (Allergan)
Drug · Other
Lead sponsor
Seegpharm S.A.
Industry
Eligibility
12 Years to 40 Years
Enrollment
2,361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
35
States / cities
Encino, California • Fullerton, California • La Mesa, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2016 · Synced Sep 6, 2026, 9:15 PM EDT
Completed Phase 2 Interventional Results available

A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer

NCT05190770
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Stage, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Stage IV
Interventions
Triamcinolone Acetonide, Oleogel-S10
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Harrison, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 6, 2026, 9:15 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Papulopustular Rosacea Study

NCT01493687
View directory record Official record
Conditions
Papulopustular Rosacea (PPR)
Interventions
CD5024, Azelaic acid 15% Gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
40
States / cities
Birmingham, Alabama • Rogers, Arkansas • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 6, 2026, 9:15 PM EDT
Completed Phase 3 Interventional Results available

Adapalene-Benzoy Peroxide (BPO) Gel in the Treatment of Acne Vulgaris as a 6-month Maintenance

NCT00687908
View directory record Official record
Conditions
Acne
Interventions
Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel, Vehicle Gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years to 35 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
27
States / cities
San Diego, California • Denver, Colorado • Longmont, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 6, 2026, 9:15 PM EDT
Completed Phase 3 Interventional Results available

A Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris

NCT00421993
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene/Benzoyl Peroxide, Adapalene, Benzoyl Peroxide, Topical Gel Vehicle
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
1,670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
33
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Fresno, California + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 6, 2026, 9:15 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Twelve Week Safety and Efficacy Study in Rosacea

NCT01784133
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
omiganan, placebo
Drug
Lead sponsor
Maruho Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
17
States / cities
Birmingham, Alabama • Santa Monica, California • New Haven, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Sep 6, 2026, 9:15 PM EDT
Terminated Phase 3 Interventional

Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers

NCT01830348
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
DSC127, placebo vehicle gel
Drug
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
25
States / cities
Mobile, Alabama • Fair Oaks, California • Fresno, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Sep 6, 2026, 9:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, 3 Day Study of Safety and Tolerability of NVN1000 Topical Gel in Healthy Volunteers

NCT01755247
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Topical Gel Vehicle, 8% NVN1000 Topical Gel, 8% NVN1000 Topical Gel and moisturizer
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Sep 6, 2026, 9:15 PM EDT
Completed Phase 3 Interventional Results available

A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel

NCT00689117
View directory record Official record
Conditions
Acne Vulgaris, Acne
Interventions
CT Gel, Clindamycin Gel (clindamycin ), Tretinoin Gel (tretinoin), Vehicle Gel
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
12 Years and older
Enrollment
1,649 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
27
States / cities
Birmingham, Alabama • Mobile, Alabama • Hot Springs, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 6, 2026, 9:15 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

NCT01355458
View directory record Official record
Conditions
Rosacea
Interventions
CD07805/47 gel, Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Clinton Township, Michigan + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 6, 2026, 9:15 PM EDT
Not listed Phase 2 Interventional

Efficacy and Safety Study of VB-1953 Topical Gel for Inflammatory Facial Acne Vulgaris

NCT03900676
View directory record Official record
Conditions
Acne Vulgaris
Interventions
VB-1953 - 2%, VB-1953 - 0% (Vehicle)
Drug
Lead sponsor
Vyome Therapeutics Inc.
Industry
Eligibility
9 Years to 45 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
12
States / cities
Ontario, California • Sherman Oaks, California • Brandon, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Sep 6, 2026, 9:15 PM EDT
Completed Phase 2 Interventional

Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses

NCT00375739
View directory record Official record
Conditions
Actinic Keratosis
Interventions
PEP005
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
24
States / cities
Huntsville, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2016 · Synced Sep 6, 2026, 9:15 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea

NCT01659853
View directory record Official record
Conditions
Erythema, Rosacea
Interventions
CD07805/47 gel 0.5%/CD07805/47 Vehicle, azelaic acid gel 15%
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
4
States / cities
Evansville, Indiana • Louisville, Kentucky • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Sep 6, 2026, 9:15 PM EDT
Completed Phase 3 Interventional Results available

Bioequivalence Study of Two Treatments in the Treatment of Acne Vulgaris on the Face

NCT03393494
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene and Benzoyl Peroxide Topical Gel, Epiduo Topical Product, Placebo
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
12 Years to 40 Years
Enrollment
825 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 7, 2021 · Synced Sep 6, 2026, 9:15 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Treatment of Asian Flushing Syndrome With Topical Alpha Agonists

NCT03497442
View directory record Official record
Conditions
Flushing, Alcohol-Related Disorders, Aldehyde Dehydrogenase Deficiency
Interventions
Brimonidine Tartrate, Placebo Vehicle Gel
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 3, 2020 · Synced Sep 6, 2026, 9:15 PM EDT
Terminated Phase 3 Interventional

Phase 3 Study Evaluating Efficacy and Safety of DSC127 Compared With Vehicle and With Standard-of-care in Diabetic Foot Ulcers

NCT01849965
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
DSC127, placebo vehicle gel, Standard of Care gel, Aquasite
Drug
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
33
States / cities
Mesa, Arizona • Phoenix, Arizona • Castro Valley, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Sep 6, 2026, 9:15 PM EDT
Completed Phase 2 Interventional Results available

A Study of CLE-400 (Topical Gel) for the Treatment of Chronic Pruritus in Adult Subjects With Notalgia Paresthetica

NCT06262607
View directory record Official record
Conditions
Chronic Pruritus in Adult Subjects With Notalgia Paresthetica (NP)
Interventions
CLE-400, Vehicle
Drug
Lead sponsor
Clexio Biosciences Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
13
States / cities
Bryant, Arkansas • Fremont, California • Coral Gables, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Sep 6, 2026, 9:15 PM EDT
Completed Phase 2 Interventional Results available

Dose-Finding Study of CD07805/47 Topical Gel in Subjects With Erythematotelangiectatic Rosacea

NCT00989014
View directory record Official record
Conditions
Erythematotelangiectatic Rosacea
Interventions
CD07805/47, CD07805/47 placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
5
States / cities
Hot Springs, Arkansas • Fort Washington, Pennsylvania • Austin, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 6, 2026, 9:15 PM EDT